• ELIVE™ therapy is delivered with the unique, custom-designed ELIVE™ CO₂ Laser System which includes the proprietary disposable hollow fiber waveguide beam delivery device
• The minimally invasive procedure can be performed by interventional cardiologists in a trans-catheter procedure (trans-femoral access)
• ELIVE™ technology and therapy is protected by a growing IP portfolio including patents and exclusive licenses and purchase agreements
• ELIVE™ differs from other laser-based heart therapies in its use of a low energy laser and a minimally invasive, disposable hollow fiber waveguide.
• Equity stake in a unique, innovative medical device company that will establish a significant paradigm shift in the treatment of heart failure
• Repeatable business model in a high growth global market
• Motivated, experienced management team
• Business model focused on realizing significant value in a relatively short time period
• Distributor/investor secures exclusive, high volume territory in interventional cardiology
• Planned exit strategy via sale to multinational healthcare company
• Robust ROI projections
• To date, ELIVE Medical has raised over €450,000 from its int’l distributor network and principals